Let's Get Real.
Clay Siegall is the co-founder of Seattle Genetics. He co-founded the company in 1998. At Seattle Genetics, Clay Siegall serves as the President of the company. He is also the Chairman of the Board and the Chief Executive Officer of the company. Clay Siegall is a scientist who specializes in cancer therapies. He has his Ph.D, which gives him the distinction of being called Dr. Clay Siegall. Dr. Clay Siegall founded Seattle Genetics on the ideas of scientific innovation, drug development, and rigorous research. Dr. Clay Siegall and the individuals within Seattle Genetics has a strong passion for the patients and assisting with finding the best plans for their healthcare. The company currently is in the development stages of antibody drug conjugates. Seattle Genetics has also secured FDA approval of their first antibody-drug conjugate product. The product is called Adcetris. Seattle Genetics has partnered with Takeda Pharmaceutical to bring the product to life. Adcetris is currently a brand that has reached global popularity. The brand is approved in more than 65 countries. After the success of Adcetris, Seattle Genetics is now in the process of developing more antibody drug conjugates, that will further the treatment of cancer.
Seattle Genetics has several licenses for the antibody drug conjugate technology. Those licenses include AbbVie, GlaxoSmithKline, Genentech, and Pfizer. This licenses between Seattle Genetics and these drug companies has generated over $350 million. In several programs, there are companies that are using the technology created by Seattle Genetics. Currently, there are 20 antibody drug conjugates in the development. Dr. Clay Siegall also is in charge of the capital raising efforts at Seattle Genetics. With his leadership in the efforts, Seattle Genetics has raised over $1.2 billion. The company raised these funds through private financing and public financing. The company had their public offering in 2001.
Prior to being the leader of Seattle Genetics, Clay Siegall worked at the Bristol-Myers Squibb Pharmaceutical Research Institute for six years. He also worked at the National Cancer Institute and the National Institutes of Health.
Clay Siegall served on the Board of Directors at several companies including, Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable.